Opinion - Coxibs: can this class of drugs survive?
Reza TabrizchiDivision of Basic Medical Sciences, Faculty of Medicine, MemorialUniversity of Newfoundland, St John’s, NL, CanadaThe sudden voluntary withdrawal of rofecoxib (Vioxx), a “selective” cyclooxygenase 2 (Cox-2) inhibitor, by Merck & Co on September 30, 2004, as a result of its adverse...
Main Author: | |
---|---|
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Dove Medical Press
2005
|
Subjects: | |
Online Access: | https://doaj.org/article/53aaa0656e1549c8b103c00be5ef8615 |
id |
ftdoajarticles:oai:doaj.org/article:53aaa0656e1549c8b103c00be5ef8615 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:53aaa0656e1549c8b103c00be5ef8615 2023-05-15T17:22:05+02:00 Opinion - Coxibs: can this class of drugs survive? Reza Tabrizchi 2005-04-01T00:00:00Z https://doaj.org/article/53aaa0656e1549c8b103c00be5ef8615 EN eng Dove Medical Press https://www.dovepress.com/opinion---coxibs-can-this-class-of-drugs-survive-peer-reviewed-article-VHRM https://doaj.org/toc/1178-2048 1178-2048 https://doaj.org/article/53aaa0656e1549c8b103c00be5ef8615 Vascular Health and Risk Management, Vol Volume 1, Pp 5-8 (2005) Diseases of the circulatory (Cardiovascular) system RC666-701 article 2005 ftdoajarticles 2022-12-31T00:57:24Z Reza TabrizchiDivision of Basic Medical Sciences, Faculty of Medicine, MemorialUniversity of Newfoundland, St John’s, NL, CanadaThe sudden voluntary withdrawal of rofecoxib (Vioxx), a “selective” cyclooxygenase 2 (Cox-2) inhibitor, by Merck & Co on September 30, 2004, as a result of its adverse cardiovascular effects (Couzin 2004), begs the question as to whether this toxicity is a class effect. There is little doubt that toxicity associated with a drug can permeate and havea devastating effect on the clinical use of the entire class to which the drug belongs, unless the nature of that toxicity is clearly defined and characterized in a transparent fashion within the scientific community. In this particular case, the jury is still out. However, unless this class of drugs is used appropriately and wisely, it will not survive. Article in Journal/Newspaper Newfoundland Directory of Open Access Journals: DOAJ Articles |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Diseases of the circulatory (Cardiovascular) system RC666-701 |
spellingShingle |
Diseases of the circulatory (Cardiovascular) system RC666-701 Reza Tabrizchi Opinion - Coxibs: can this class of drugs survive? |
topic_facet |
Diseases of the circulatory (Cardiovascular) system RC666-701 |
description |
Reza TabrizchiDivision of Basic Medical Sciences, Faculty of Medicine, MemorialUniversity of Newfoundland, St John’s, NL, CanadaThe sudden voluntary withdrawal of rofecoxib (Vioxx), a “selective” cyclooxygenase 2 (Cox-2) inhibitor, by Merck & Co on September 30, 2004, as a result of its adverse cardiovascular effects (Couzin 2004), begs the question as to whether this toxicity is a class effect. There is little doubt that toxicity associated with a drug can permeate and havea devastating effect on the clinical use of the entire class to which the drug belongs, unless the nature of that toxicity is clearly defined and characterized in a transparent fashion within the scientific community. In this particular case, the jury is still out. However, unless this class of drugs is used appropriately and wisely, it will not survive. |
format |
Article in Journal/Newspaper |
author |
Reza Tabrizchi |
author_facet |
Reza Tabrizchi |
author_sort |
Reza Tabrizchi |
title |
Opinion - Coxibs: can this class of drugs survive? |
title_short |
Opinion - Coxibs: can this class of drugs survive? |
title_full |
Opinion - Coxibs: can this class of drugs survive? |
title_fullStr |
Opinion - Coxibs: can this class of drugs survive? |
title_full_unstemmed |
Opinion - Coxibs: can this class of drugs survive? |
title_sort |
opinion - coxibs: can this class of drugs survive? |
publisher |
Dove Medical Press |
publishDate |
2005 |
url |
https://doaj.org/article/53aaa0656e1549c8b103c00be5ef8615 |
genre |
Newfoundland |
genre_facet |
Newfoundland |
op_source |
Vascular Health and Risk Management, Vol Volume 1, Pp 5-8 (2005) |
op_relation |
https://www.dovepress.com/opinion---coxibs-can-this-class-of-drugs-survive-peer-reviewed-article-VHRM https://doaj.org/toc/1178-2048 1178-2048 https://doaj.org/article/53aaa0656e1549c8b103c00be5ef8615 |
_version_ |
1766108358862962688 |